Navigation Links
Bioniche Pharma Acquires Baxter's ENLON(R) and ENLON-PLUS(R)

Three new products coming soon to Bioniche's growing line of injectable


LAKE FOREST, Ill., July 2 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the acquisition of Baxter Healthcare Corporation's ENLON product line, including:

-- ENLON(R) (edrophonium chloride injection, USP) 10 mg/mL, 15 mL vial

-- ENLON-PLUS(R) (edrophonium chloride, USP and atropine sulfate, USP)

Injection 5 mL ampule

-- ENLON-PLUS(R) (edrophonium chloride, USP and atropine sulfate, USP)

Injection, 15 mL Multi-dose Vial

Bioniche purchased the rights and certain assets related to the ENLON(R) product line from Baxter, which discontinued ENLON(R) in February 2008. Bioniche anticipates launching all three codes of ENLON(R) in October 2008.

"We are pleased to reintroduce these products, providing health care professionals with access to additional options," said Steve Thornton, CEO Bioniche Pharma.

According to IMS data, 2007 sales of ENLON(R) and ENLON-PLUS(R) totaled $2,727,000 and 307,000 units.


ENLON(R) is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. ENLON(R) is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.

ENLON-PLUS(R) (edrophonium chloride, USP and atropine sulfate, USP) Injection is recommended as a reversal agent or antagonist of nondepolarizing neuromuscular blocking agents. It is not effective against depolarizing neuromuscular blocking agents. It is also useful if used adjunctively in the treatment of respiratory depression caused by curare overdosage.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology and dermatology. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at


SOURCE Bioniche Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bioniche Reports Fiscal 2007 Year-End Results
2. Pharmacy Students Taught Improved Medication Adherence and Holistic Health Services Through Program Incorporating InforMedixs Med-eXpert(TM) System
3. Transcept Pharmaceuticals Appoints Key Senior Executives
4. Aureus Pharma Announces Date of 2008 Annual User Symposium
5. WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR
6. Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications
7. CET Life Sciences Center Welcomes Belmont University School of Pharmacy as New Tenant
8. Pharmasset Joins Russell 3000 Index
9. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
10. Webcast Alert: Isis Pharmaceuticals Announces a Business Update Conference Call
11. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... United States ," said Andrew Rae ... advancements regarding iCo-008 are not only value enriching ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
Breaking Biology Technology:
(Date:10/27/2015)... NEW YORK , Oct. 27, 2015 ... the major issues of concern for various industry verticals ... This is due to the growing demand for secure ... practices in various ,sectors, such as hacking of bank ... concerns for electronic equipment such as PC,s, laptops, and ...
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... announced that Google has adopted the Synaptics ® ... solutions to power its newest flagship smartphones, the Nexus ... --> --> ... to provide strategic collaboration in the joint development of ...
(Date:10/26/2015)... PALO ALTO, Calif. and LAS ... – Nok Nok Labs , an innovator in ... FIDO Alliance , today announced the launch of its ... the first unified platform enabling organizations to use standards-based ... authentication. The Nok Nok S3 Authentication Suite is ideal ...
Breaking Biology News(10 mins):